Alkermes Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes or view top-rated stocks.

Wall Street analysts have given Alkermes a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alkermes wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for Alkermes.

Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings data on Tuesday, April, 27th. The company reported $0.11 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.13. The firm had revenue of $251.43 million for the quarter, compared to analyst estimates of $233.78 million. Alkermes had a negative trailing twelve-month return on equity of 0.15% and a negative net margin of 9.06%. The business's revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.01 earnings per share.
View Alkermes' earnings history.

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALKS shares have increased by 58.6% and is now trading at $25.77.
View which stocks have been most impacted by COVID-19.

Alkermes issued an update on its FY 2021 earnings guidance on Wednesday, July, 28th. The company provided EPS guidance of $0.520-$0.700 for the period, compared to the Thomson Reuters consensus estimate of $0.510. The company issued revenue guidance of $1.15 billion-$1.19 billion, compared to the consensus revenue estimate of $1.14 billion.

6 equities research analysts have issued 12-month target prices for Alkermes' stock. Their forecasts range from $15.00 to $29.00. On average, they expect Alkermes' stock price to reach $22.20 in the next twelve months. This suggests that the stock has a possible downside of 13.9%.
View analysts' price targets for Alkermes or view top-rated stocks among Wall Street analysts.

119 employees have rated Alkermes CEO Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among Alkermes' employees.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of ALKS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALKS stock can currently be purchased for approximately $25.77.

Alkermes has a market capitalization of $4.13 billion and generates $1.04 billion in revenue each year. The company earns $-110,860,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

Alkermes employs 2,245 workers across the globe.

The official website for Alkermes is www.alkermes.com.

Alkermes is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at (531) 772-8000 or via email at [email protected]